Artificial exosomes for translational nanomedicine

Journal of Nanobiotechnology, Journal Year: 2021, Volume and Issue: 19(1)

Published: Aug. 12, 2021

Abstract Exosomes are lipid bilayer membrane vesicles and emerging as competent nanocarriers for drug delivery. The clinical translation of exosomes faces many challenges such massive production, standard isolation, loading, stability quality control. In recent years, artificial based on nanobiotechnology to overcome the limitations natural exosomes. Major types include ‘nanovesicles (NVs)’, ‘exosome-mimetic (EM)’ ‘hybrid (HEs)’, which obtained by top-down, bottom-up biohybrid strategies, respectively. Artificial powerful alternatives Here, we outline advances in through discuss their strengths, future perspectives. development holds great values translational nanomedicine.

Language: Английский

---

Cancer nanotechnology: current status and perspectives

Nano Convergence, Journal Year: 2021, Volume and Issue: 8(1)

Published: Nov. 2, 2021

Modern medicine has been waging a war on cancer for nearly century with no tangible end in sight. Cancer treatments have significantly progressed, but the need to increase specificity and decrease systemic toxicities remains. Early diagnosis holds key improving prognostic outlook patient quality of life, diagnostic tools are cusp technological revolution. Nanotechnology steadily expanded into reaches chemotherapy, radiotherapy, diagnostics, imaging, demonstrating capacity augment each advance care. Nanomaterials provide an abundance versatility, functionality, applications engineer specifically targeted medicine, accurate early-detection devices, robust imaging modalities, enhanced radiotherapy adjuvants. This review provides insights current clinical pre-clinical nanotechnological drug therapy, radiation therapy.

Language: Английский

---

Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment

Advanced Drug Delivery Reviews, Journal Year: 2021, Volume and Issue: 176, P. 113891 - 113891

Published: July 26, 2021

CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, extensity used human diseases treatment, especially cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by are established. However, significant challenges remain clinical applications. The greatest challenge therapy how safely efficiently deliver it target sites in vivo. Nanotechnology has greatly contributed drug delivery. Here, we present the action mechanisms CRISPR/Cas9, application focus on nanotechnology-based delivery gene editing immunotherapy pave way translation. We detail difficult barriers CRISIR/Cas9 vivo discuss relative solutions encapsulation, delivery, controlled release, cellular internalization, endosomal escape.

Language: Английский

---

Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications

Journal of Controlled Release, Journal Year: 2022, Volume and Issue: 353, P. 1127 - 1149

Published: Dec. 26, 2022

Language: Английский

---

Extracellular Microvesicles as New Industrial Therapeutic Frontiers

Trends in biotechnology, Journal Year: 2019, Volume and Issue: 37(7), P. 707 - 729

Published: Jan. 9, 2019

Language: Английский

---

Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss

Bioactive Materials, Journal Year: 2021, Volume and Issue: 6(9), P. 2905 - 2913

Published: Feb. 23, 2021

The differentiation shift from osteogenesis to adipogenesis of bone marrow mesenchymal stem cells (BMSCs) characterizes many pathological loss conditions. Stromal cell-derived factor-1 (SDF1) is highly enriched in the for C-X-C motif chemokine receptor 4 (CXCR4)-positive hematopoietic cell (HSC) homing and tumor metastasis. In this study, we displayed CXCR4 on surface exosomes derived genetically engineered NIH-3T3 cells. CXCR4+ selectively accumulated marrow. Then, fused with liposomes carrying antagomir-188 produce hybrid nanoparticles (NPs). NPs specifically gathered released antagomir-188, which promoted inhibited BMSCs thereby reversed age-related trabecular decreased cortical porosity mice. Taken together, study presents a novel way obtain bone-targeted via display promising anabolic therapeutic approach loss.

Language: Английский

---

Approaches to surface engineering of extracellular vesicles

Advanced Drug Delivery Reviews, Journal Year: 2021, Volume and Issue: 173, P. 416 - 426

Published: April 6, 2021

Language: Английский

---

Camouflage strategies for therapeutic exosomes evasion from phagocytosis

Journal of Advanced Research, Journal Year: 2021, Volume and Issue: 31, P. 61 - 74

Published: Jan. 12, 2021

Even though exosome-based therapy has been shown to be able control the progression of different pathologies, data revealed by pharmacokinetic studies warn low residence time exogenous exosomes in circulation that can hinder clinical translation therapeutic exosomes. The macrophages related organs mononuclear phagocytic system are responsible primarily for rapid clearance and retention exosomes, which strongly limits amount exosomal particles available reach target tissue, accumulate it release with high efficiency its cargo acceptor cells exert desired biological effect. Endowing surface modifications evade immune is a plausible strategy contribute suppression increase their targeted content delivery. Here, we summarize current evidence about mechanisms underlying recognition sequestration cells. Also, propose strategies generate 'invisible' system, through incorporation anti-phagocytic molecules on exosomes' allow increasing circulating half-life purpose bioavailability transfer molecular improve efficacy profile. Macrophage-mediated phagocytosis main behind short systemically injected hindering Exosomes 'Camouflage Cloak' using antiphagocytic inhibition clearance, hence, on-target Some candidate could an role CD47, CD24, CD44, CD31, β2M, PD-L1, App1, DHMEQ. Pre- post-isolation methods exosome engineering compatible loading expression molecules.

Language: Английский

---

Peroxidase-like Active Nanomedicine with Dual Glutathione Depletion Property to Restore Oxaliplatin Chemosensitivity and Promote Programmed Cell Death

ACS Nano, Journal Year: 2022, Volume and Issue: 16(3), P. 3647 - 3663

Published: March 10, 2022

The nanocatalytic activity of nanozymes provides a vision for tumor treatment. However, the glutathione (GSH)-related antioxidant defense system (ADS) formed on basis excessive GSH in microenvironment limits its catalytic activity. Here, dendritic mesoporous silica nanoparticles (DMSNs) were employed as nanocarrier; ultrasmall Fe3O4 nanoparticles, Mn2+ ions, and glutaminase inhibitor Telaglenastat (CB-839) subsequently integrated into large mesopores DMSNs, forming DMSN/Fe3O4–Mn@CB-839 (DFMC) nanomedicine. This nanomedicine exhibits peroxidase mimicking activities under acidic conditions, which catalyzes decomposition hydrogen peroxide (H2O2) hydroxyl radical (•OH). also promotes formation lipid peroxides, is required ferroptosis. Furthermore, this can effectively deplete existing GSH, thereby enhancing reactive oxygen species (ROS)-mediated therapy. Moreover, introduced CB-839 blocks endogenous synthesis further depletion performance, reduces excretion oxaliplatin (GSH-related resistance) from cells, restoring chemical sensitivity oxaliplatin. dual property significantly weakens GSH-related ADS restores oxaliplatin, leading to high DFMC-induced apoptosis ferroptosis cells. Our developed based nanotechnology clinical drug may aid development

Language: Английский

---

Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer

Journal of Nanobiotechnology, Journal Year: 2022, Volume and Issue: 20(1)

Published: Jan. 25, 2022

Although cisplatin-based chemotherapy has been used as the first-line treatment for ovarian cancer (OC), tumor cells develop resistance to cisplatin during treatment, causing poor prognosis in OC patients. Studies have demonstrated that overactivation of phosphatidylinositol 3-kinase/protein kinase B/mammalian target rapamycin (PI3K/AKT/mTOR) pathway is involved chemoresistance and overexpression microRNA-497 (miR497) may overcome by inhibiting mTOR pathway. However, low transcriptional efficiency unstable chemical properties miR497 limit its clinical application. Additionally, triptolide (TP) was confirmed possess a superior killing effect on cisplatin-resistant cell lines, partially through Even so, applications TP are restricted serious systemic toxicity weak water solubility.Herein, whether combined application could further synergically suppressing signaling investigated. Bioinspired hybrid nanoparticles formed fusion CD47-expressing exosomes cRGD-modified liposomes (miR497/TP-HENPs) were prepared codeliver TP. In vitro results indicated efficiently taken up cells, thus significantly enhancing apoptosis. Similarly, effectively enriched areas exerted significant anticancer activity without any negative effects vivo. Mechanistically, they promoted dephosphorylation overactivated PI3K/AKT/mTOR pathway, boosted reactive oxygen species (ROS) generation upregulated polarization macrophages from M2 M1 macrophages.Overall, our findings provide translational strategy offer potential solution other tumors.

Language: Английский

---